Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin (Q45423860)

14 December 2017

Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin (English)

1 reference

14 December 2017

vaccinia virus

1 reference

Agnes Jones-Trower

1

1 reference

14 December 2017

Alonzo Garcia

2

1 reference

14 December 2017

Clement A Meseda

3

1 reference

14 December 2017

Yong He

4

1 reference

14 December 2017

Carol Weiss

5

1 reference

14 December 2017

Arunima Kumar

6

1 reference

14 December 2017

Jerry P Weir

7

1 reference

14 December 2017

Michael Merchlinsky

8

1 reference

14 December 2017

language of work or name

English

0 references

publication date

13 September 2005

1 reference

14 December 2017

13

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

14 December 2017

343

1 reference

14 December 2017

1

1 reference

14 December 2017

128-140

1 reference

Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Dose-dependent neutralizing-antibody responses to vaccinia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

A luminescent ruthenium complex for ultrasensitive detection of proteins immobilized on membrane supports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Pathogenesis and potential antiviral therapy of complications of smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Vaccinia virus transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Cysteine scanning mutagenesis at 40 of 76 positions in villin headpiece maps the F-actin binding site and structural features of the domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Smallpox vaccination: a review, part II. Adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Neutralizing and protective antibodies directed against vaccinia virus envelope antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Repression of vaccinia virus Holliday junction resolvase inhibits processing of viral DNA into unit-length genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

The looming threat of bioterrorism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Identification of a vaccinia virus penetration protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Experience of anti-vaccinia immunoglobulin in the United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

The formation and function of extracellular enveloped vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Identification of antigenic determinants by polyclonal and hybridoma antibodies induced during the course of infection by vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Identification of the gene encoding vaccinia virus immunodominant protein p35.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Mapping and nucleotide sequence of the vaccinia virus gene that encodes a 14-kilodalton fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.08.008

1 reference

14 December 2017

1 reference